TABLETING
ver the past several years major pharmaceutical producers have started adopting continuous manufacturing methods for oral solid dosage forms, both for development as well as commercial production. With the approval of a number of drugs produced continuously as well as the ICH Q13 and “Quality Considerations for Continuous Manufacturing Guidance for Industry” of the FDA being close to release, the industry is gaining further confi dence in implementing the technology. However, continuous manufacturing has not seen the breakthrough as paradigm shift predicted by many yet. Batch manufacturing is still a default platform for many new drug products, but a change of mindset has started to turn this around. Most early equipment (built in the
O
past 15 years) used for continuous manufacturing of oral solid dosage forms was designed for medium product volumes (e.g. matching a tableting capacity of 25-50kg/h) and low potency drugs. T is fact made it diffi cult for many pharmaceutical companies to justify a business case around switching from batch to continuous. T e benefi ts of going for continuous manufacturing simply didn’t outweigh the higher investment costs in more complex equipment, higher API consumption during early development and the formation of new production teams familiar with highly complex equipment. And put simply, the relative high production volumes did not fi t with the pipeline of most new drug products. Gericke has been one of the leading companies in developing and commercialising continuous feeding and blending equipment to produce oral solid dosage forms. It presented the fi rst formulation skid at Achema 2012 and has since successfully supplied the continuous manufacturing. T e company has also additionally realised the demand for
Continuous
manufacturing is no longer just a
trend; it’s a proven recipe for success
MANUFACTURING EVOLUTION CONTINUOUS The rising popularity of a future-focused approach to tableting
equipment specifi cally for the other ends of the spectrum: low-volume, high potent and high-volume drug products. For low volume, high potent drugs, a semi continuous feeding and blending unit (the Gericke Formulation Skid Batch GFS-B) was developed. T e main benefi ts are around reduced API consumption during development, no start up and shut down losses, less complex control strategy as well as suitability for very low dosages (below 1% drug load) and high containment (OEB4/5). T is enables the use of continuous manufacturing for batch sizes below 1kg. For high-volume products a new
Gericke Formulation Skid (GFS)
variant of the Gericke Formulation Skid Conti GFS-C can be used. T is is a traditional continuous feeding and blending approach suitable for high throughputs up to 500 kg/h and even the supply of multiple tableting or capsule fi lling lines with a single blending unit. T is allows business cases to be built around operational costs as an additional
benefi t of continuous manufacturing. T is solution is very attractive for generics manufacturers or over-the- counter products.
GRAVIMETRIC FEEDING AND BLENDING SOLUTIONS With around 50 continuous blenders installed for pharmaceutical applications, Gericke is a key player in providing fl exible and modular feeding and blending solutions for the continuous production of oral solid dosage forms. Systems rold in 2021 ranged from gravimetric feeders and blender integrated into isolators, semi continuous blending for direct compression, modular units with eight gravimetric feeders as well as high volume lines supplying multiple double sided rotary tablet presses. With installations all over the world, it goes to show that continuous manufacturing is not only a trend and will soon become the paradigm shift everyone is hoping for.
www.scientistlive.com 47
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60
